Építés alatt – nem éles oldal
Belépés

NCT06304805Befejeződött1. fázis

TGRX-326 Pharmacokinetic Food Effect Bioavailability Study

A Randomized, Open-label, Single-dose, 3-cycle, 6-sequence, Crossover Study Evaluating Food Effect on Pharmacokinetic Profiles of TGRX-326 in Chinese Healthy Subjects and Effect of Drug Specification on Bioavailability in Human

Forrás: ClinicalTrials.gov · Utoljára frissítve: 2025. máj. 18.

Következő lépések

Rövid összefoglaló (regiszter, angolul)

A study evaluating the effects of food intake on the pharmacokinetic (PK) profiles of TGRX-326 and the effect of different drug specifications on human bioavailability for TGRX-326, a drug indicated for non-small cell lung cancer treatment

Állapot (regiszter)
Befejeződött
Fázis (regiszter)
1. fázis
Vizsgálattípus
Beavatkozással járó
Résztvevők száma
24 (tényleges)
Első benyújtás
2024. márc. 5.
Kezdés
2023. dec. 13.
Elsődleges befejezés
2024. jan. 12.
Fő szponzor
Shenzhen TargetRx Co., Ltd.
Betegségek
Tüdőrák
NCT-szám
NCT06304805

Mit vállalsz

  • Vizsgálat típusa: Beavatkozással járó · 1. fázis
  • Bevont résztvevők: 24
  • 2023. dec. 13. és az elsődleges befejezés (2024. jan. 12.) között
  • 1 helyszín, 1 országban
  • Vizitek és vizsgálatok: kérdezd a vizsgálat csapatát, a regiszter nem sorolja fel őket

A(z) ClinicalTrials.gov regisztermezőiből összeállítva. A vizsgálat felépítését írja le.

Ki nem vehet részt

Szó szerint a(z) ClinicalTrials.gov forrásból, témák szerint csoportosítva. Hogy ki vehet részt, azt csak a vizsgálat csapata dönti el.

Korábbi kezelés

  • history of major surgery within 3 months before first dose, or have plans to receive surgery during the study, or history of any surgery that could affect drug absorption, distribution, metabolism and excretion
  • use of any investigational drug or participation of any clinical study (for drug or medical device) within 3 months before first dose, or cannot participate the study in person/on site
  • history of blood donation, blood loss (>= 400 mL, excluding normal blood loss during female menstrual period), or reception of blood transfusion within 3 months before screening
  • history of daily cigarette consumption of more than 5 within 3 months before screening, or cannot avoid using cigarette/tabacco products during the study
  • history of alcohol abuse (more than 14 units of alcohol per week) within 3 months before screening, or cannot avoid alcohol consumption during study
  • history of large tea/coffee/caffeinated drink intake (more than 8 cups per day) within 3 months before first dose
  • use of any prescription / over-the-counter drug, or Chinese herbal medication, or health supplementary products within 14 days of test article administration
  • vaccination within 14 days before first test article administration, or have plans to receive vaccination during the study period
  • history of unprotected sexual activities within 14 days before first dose
  • consumption of food or drink rich in caffeine/xanthine (such as chocolate, coffee, tea, coke) or food/food product of grapefruit, dragon fruit, mango, tangerine, or any food that could affect drug absorption, distribution, metabolism and excretion

Más betegség

  • history of allergic reactions, or allergic to any components to the study drugs that by investigator's judgement unsuitable for the study
  • any clinically significant conditions that could affect study outcomes, safety or compliance
  • have difficulties to receive venous needle puncture, or cannot tolerate venous needle puncture, or history of hematophobia or needle sickness
  • history of substance abuse
  • any one positive result for hepatitis-B surface antigen, Hepatitis C antibody, HIV antibody or syphilis antibody

Laborértékek

  • history of irregular dietary schedule within 1 months of first dose (including, dieting, overeating, low sodium intake, etc.)

Egyéb

  • have special food requirement or cannot follow food requirement of the study, or lactose intolerant
  • alcohol breathing test results of > 0.0 mg/100mL for blood alcohol concentration
  • positive test results on substance use (including, morphine, methylamphetamine, ketamine, tetrahydrocannabinol, methylene-dioxy-methyl-amphetamine)
  • female in pregnancy or breastfeeding period, or positive pregnancy test result
  • any reasons that is deemed unsuitable for study participation as determined by investigator

Kiket keres a vizsgálat

  • able to understand the purpose, methods and possible adverse events of the study and agree to volunteering consent before the start of study
  • healthy subject; male or female
  • Age between 18 and 55 (inclusive)
  • body mass index (BMI) between 19.0 and 26.0 (inclusive), male weight <=50 kg, female weight <=45 kg
  • normal/ clinically insignificant test results (including physical exam, laboratory tests, 12-lead ECG, chest x-ray, etc.)
  • participant/partner of the participant does not have plans for child bearing from screening until 6 months after study, and is willing to take contraceptive measures during study period and for 6 months, and does not have plans to donate sperm/egg during the said period

Életkor a regiszterben: 18 év – 55 év · Nem: nők és férfiak · Egészséges önkénteseket is fogad

A teljes feltétellista: ClinicalTrials.gov

Helyszínek (1)

Helyszínek a regiszter sorrendjében. Ha a profilodba mented a városodat, távolság szerint rendeződnek.

HelyszínVárosOrszágHelyszín állapota
First Affiliated Hospital Bengbu Medical CollegeBengbuKínaIsmeretlen állapot

Te vagy a koordinátor? Erősítsd meg az adatokat

Ez az oldal tájékoztatás, nem orvosi tanács. Bármely vizsgálatról az orvosoddal beszélj.